Dabrafenib Recruiting Phase 2 Trials for Tumor Skin / Melanoma Stage IIIb-IVM1a / BRAF Gene Mutation / Metastasis Skin / Melanoma (Skin) / Melanoma Stage IIIb-IVM1B Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03972046Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma